Nomogram and competing risk model to predict recurrence after curative surgical resection of PDAC

被引:6
作者
Ge, Jia-chen [1 ]
Tao, Ming [1 ]
Li, Lei [1 ]
Ma, Zhao-lai [1 ]
Jiang, Bin [1 ]
Yuan, Chun-hui [1 ]
Wang, Hang-yan [1 ]
Peng, Ying [1 ]
Xiu, Dian-rong [1 ]
机构
[1] Peking Univ Third Hosp, Dept Gen Surg, Beijing, Peoples R China
关键词
Pancreatic ductal adenocarcinoma; Local recurrence; Distant metastasis; Nomogram; Recurrence free survival; Competing risk model; PANCREATIC DUCTAL ADENOCARCINOMA; ISOLATED LOCAL RECURRENCE; CIRCULATING TUMOR-CELLS; PROGNOSTIC NOMOGRAM; RE-RESECTION; CANCER; SURGERY; GEMCITABINE; DEFINITION; CONSENSUS;
D O I
10.1016/j.pan.2021.04.010
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Surgical resection remains the only potentially curative treatment for pancreatic ductal adenocarcinoma (PDAC). However, a number of patients get disease recurred in a short time postoperation. Few studies have focused on the predictors of different recurrence patterns of PDAC. Objective: To try to establish and verify a nomogram to predict recurrence free survival (RFS) in PDAC patients, and to distinguish the risk factors of local recurrence first and distant metastasis first via competing risk model. Methods: Patients who underwent radical pancreatectomy for PDAC in our center from 2010 to 2018 were reviewed retrospectively. Kaplan-Meier methods and multivariate Cox regression analyses were used to identify the clinicopathological predictors of recurrence post-operation. And then, a nomogram was constructed and validated. Competing risk regression model was used to compare the predictors between local recurrence group and distant metastasis group. Results: A total of 200 patients were included into the final analysis, and 153 patients got disease relapsed post-operation. CA19-9 level, vascular resection, tumor differentiation, lymph node ratio (LNR) and adjuvant chemotherapy were identified as independent risk factors for recurrence free survival (RFS) and incorporated into the nomogram. The C-index of the nomogram was 0.650. Competing risk model indicated that the status of lymph-node metastasis was significantly associated the patterns of first relapse. Conclusions: Nomogram and competing risk model were constructed to quantify the risk of recurrence following surgery for PDAC. Our findings may be useful for predicting RFS and recurrence pattern in clinical work. (c) 2021 IAP and EPC. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:1102 / 1111
页数:10
相关论文
共 52 条
  • [1] Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas
    Brennan, MF
    Kattan, MW
    Klimstra, D
    Conlon, K
    [J]. ANNALS OF SURGERY, 2004, 240 (02) : 293 - 298
  • [2] Acquisition of Portal Venous Circulating Tumor Cells From Patients With Pancreaticobiliary Cancers by Endoscopic Ultrasound
    Catenacci, Daniel V. T.
    Chapman, Christopher G.
    Xu, Peng
    Koons, Ann
    Konda, Vani J.
    Siddiqui, Uzma D.
    Waxman, Irving
    [J]. GASTROENTEROLOGY, 2015, 149 (07) : 1794 - +
  • [3] Modeling the cumulative incidence function of multivariate competing risks data allowing for within-cluster dependence of risk and timing
    Cederkvist, Luise
    Holst, Klaus K.
    Andersen, Klaus K.
    Scheike, Thomas H.
    [J]. BIOSTATISTICS, 2019, 20 (02) : 199 - 217
  • [4] Vascular Resection for Pancreatic Cancer: 2019 French Recommendations Based on a Literature Review From 2008 to 6-2019
    Delpero, Jean Robert
    Sauvanet, Alain
    [J]. FRONTIERS IN ONCOLOGY, 2020, 10
  • [5] Validation of a postresection pancreatic adenocarcinorna nomogram for disease-specific survival
    Ferrone, CR
    Kattan, MW
    Tomlinson, JS
    Thayer, SP
    Brennan, MF
    Warshaw, AL
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (30) : 7529 - 7535
  • [6] Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study
    Gbolahan, Olumide B.
    Tong, Yan
    Sehdev, Amikar
    O'Neil, Bert
    Shanda, Safi
    [J]. BMC CANCER, 2019, 19 (1)
  • [7] Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma
    Groot, Vincent P.
    Gemenetzis, Georgios
    Blair, Alex B.
    Rivero-Soto, Roberto J.
    Yu, Jun
    Javed, Ammar A.
    Burkhart, Richard A.
    Rinkes, Inne H. M. Borel
    Molenaar, I. Quintus
    Cameron, John L.
    Weiss, Matthew J.
    Wolfgang, Christopher L.
    He, Jin
    [J]. ANNALS OF SURGERY, 2019, 269 (06) : 1154 - 1162
  • [8] Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma
    Groot, Vincent P.
    Rezaee, Neda
    Wu, Wenchuan
    Cameron, John L.
    Fishman, Elliot K.
    Hruban, Ralph H.
    Weiss, Matthew J.
    Zheng, Lei
    Wolfgang, Christopher L.
    He, Jin
    [J]. ANNALS OF SURGERY, 2018, 267 (05) : 936 - 945
  • [9] Systematic review on the treatment of isolated local recurrence of pancreatic cancer after surgery; re-resection, chemoradiotherapy and SBRT
    Groot, Vincent P.
    van Santvoort, Hjalmar C.
    Rombouts, Steffi J. E.
    Hagendoorn, Jeroen
    Rinkes, Inne H. M. Bore
    van Vulpen, Marco
    Herman, Joseph M.
    Wolfgang, Christopher L.
    Besselink, Marc G.
    Molenaar, I. Quintus
    [J]. HPB, 2017, 19 (02) : 83 - 92
  • [10] A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma
    Guo, Shi-wei
    Shen, Jing
    Gao, Jun-hui
    Shi, Xiao-han
    Gao, Sui-zhi
    Wang, Huan
    Li, Bo
    Yuan, Wei-lan
    Lin, Ling
    Jin, Gang
    [J]. SURGERY, 2020, 168 (06) : 1003 - 1014